Study · Animal study (in vivo) · mouse · 2017
9 resultsIwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, Horikawa T, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanabe M, Nabeshima K, Iwasaki A, Yanase T
Endocrinology1 Dec 2017Cited by 76 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
9 results from studies that gave the peptide. No result from this study comes from people.
In athymic mice with MCF-7 xenografts, exendin‑4 reduced tumor size.
In plain wordsIn mice with MCF-7 tumors, exendin‑4 reduced tumor size.
mousen: not reported in source
MCF-7 xenograft in athymic miceSource sentences
When MCF-7 cells were transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo.
In mice with MCF-7 tumors, exendin‑4 significantly reduced tumor cell proliferation measured by Ki67 staining.
In plain wordsIn mice with MCF-7 tumors, exendin‑4 reduced tumor cell multiplication.
mousen: not reported in source
MCF-7 xenograft in athymic miceSource sentences
Ki67 immunohistochemistry revealed that breast cancer cell proliferation was significantly reduced in tumors extracted from Ex-4-treated mice.
When MCF-7 cells were transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo.
In breast cancer cells, exendin‑4 significantly reduced cell number in a dose-dependent manner.
In plain wordsIn cells, exendin‑4 reduced breast cancer cell numbers as the dose increased.
humann: not reported in source
breast cancer cellsSource sentences
We found that 0.1 to 10 nM Ex-4 significantly decreased the number of breast cancer cells in a dose-dependent manner.
In breast cancer cells, exendin‑4 did not induce apoptosis.
In plain wordsIn cells, exendin‑4 did not induce breast cancer cell death by apoptosis.
humann: not reported in source
breast cancer cellsSource sentences
Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation significantly and dose-dependently.
In breast cancer cells, exendin‑4 significantly reduced proliferation in a dose-dependent manner.
In plain wordsIn cells, exendin‑4 reduced breast cancer cell multiplication as the dose increased.
humann: not reported in source
breast cancer cellsSource sentences
Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation significantly and dose-dependently.
In MCF-7 cells, exendin‑4 significantly inhibited NF-κB nuclear translocation.
In plain wordsIn cells, exendin‑4 reduced NF-κB movement into the nucleus.
humann: not reported in source
MCF-7 cellsSource sentences
In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression.
In MCF-7 cells, exendin‑4 significantly inhibited NF-κB target gene expression.
In plain wordsIn cells, exendin‑4 reduced NF-κB target gene expression.
humann: not reported in source
MCF-7 cellsSource sentences
In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression.
In MCF-7 cells, exendin‑4 reduced Akt phosphorylation.
In plain wordsIn cells, exendin‑4 reduced Akt phosphorylation.
humann: not reported in source
MCF-7 cellsSource sentences
Furthermore, Ex-4 decreased both Akt and IκB phosphorylation.
In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression.
In MCF-7 cells, exendin‑4 reduced IκB phosphorylation.
In plain wordsIn cells, exendin‑4 reduced IκB phosphorylation.
humann: not reported in source
MCF-7 cellsSource sentences
Furthermore, Ex-4 decreased both Akt and IκB phosphorylation.
In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated